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Objectives: The prognosis in patients with hepatocellular carcinoma (HCC) accompanied by main portal
vein tumour thrombus (MPVTT) is poor. The aim of this study was to clarify the factors linked to survival
of >5 years after hepatectomy in HCC patients with MPVTT.
Methods: Twenty-nine HCC patients with MPVTT were divided into two groups comprising, respectively,
patients who survived >5 years after hepatectomy (survivors, n = 5) and those who did not (non-survivors,
n = 24). The two groups were compared.
Results: Overall survival rates at 1, 3 and 5 years were 62.1%, 24.1% and 17.2%, respectively. Four
(80.0%) 5-year survivors had recurrences of HCC in which the number of recurrent nodules was under
four. Three (21.4%) of the 14 non-survivors who underwent curative resection experienced recurrences of
HCC and all of them demonstrated fewer than four recurrent nodules (P = 0.0114). Local therapy, such as
radiofrequency ablation and resection of recurrence, had more often been used in survivors than in
non-survivors (P = 0.0364).
Conclusions: Although surgical outcomes in patients with HCC accompanied by MPVTT are unsatis-
factory, some patients do enjoy longterm survival. When the number of recurrent nodules is less than four,
local therapy should be selected with the aim of achieving 5-year survival.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant
diseases in the world.1 In particular, HCC with tumour thrombus
in the first branch of the portal vein (Vp3) or with tumour throm-
bus in the main portal trunk or the opposite side portal branch
(Vp4) is considered to represent an end-stage condition with a
poor prognosis because tumour cells are likely to have spread
throughout the liver.2 In recent reports,3,4 HCC patients with main
portal vein tumour thrombus (MPVTT) are described as surviv-
ing only 2.7–4.0 months if left untreated. Hepatic resection
remains the only potentially curative treatment for such patients.
However, in patients who undergo hepatic resection for HCCwith
MPVTT (Vp3 and Vp4), postoperative 5-year survival rates are
only 10–30%.5–9 Nevertheless, there are a few 5-year survivors. Ikai
et al.5 reported a 5-year survival rate of 10.9% (four patients) and
Le Treut et al.6 reported the 5-year survival of two of 22 patients
with HCC accompanied by MPVTT.
This study retrospectively investigated the clinical and patho-
logical characteristics of 29 HCC patients with MPVTT in an
attempt to clarify the factors determining 5-year survival in
patients with HCC accompanied by MPVTT.
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Materials and methods
Patients
This study included 692 HCC patients who underwent liver resec-
tion between 1985 and 2005 at the Department of Surgery and
Science, Kyushu University Hospital. Preoperative ultrasonogra-
phy (US), computed tomography (CT), magnetic resonance
imaging (MRI), angiography and CT during angiography were
performed in all patients. From a retrospective database, 29
patients (4.2%) with tumour invasion of the first branch of the
portal vein (Vp3) and tumour in the main portal trunk or the
opposite side portal branch (Vp4) were enrolled in this study.
These included 25 male and four female patients with a median
age of 55 years (range: 29–76 years). Among these patients, 12
(41.4%) were infected with hepatitis C virus (HCV) and 16
(55.2%) with hepatitis B virus (HBV). The median finding on the
indocyanine green retention test at 15 min (ICGR15) was 11.4%
(range: 1.4–33.6%).
Methods
The 29 patients were divided into two groups consisting of those
who survived for >5 years after hepatectomy (5-year survivors,
n = 5) and those who did not (non-survivors, n = 24). Possible
preoperative prognostic factors investigated in both groups in-
cluded age, sex, HBV surface antigen, anti-HCV antibody, ICGR15
result, albumin, total bilirubin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alpha fetoprotein (AFP) and des-
g-carboxy prothrombin (DCP). Various cancer-related factors
including maximum tumour size, tumour grade (good, moderate
or poor) and the presence of intrahepatic metastases were also
examined. Our institutional review board approved the study
protocol, which conformed to the Helsinki Declaration of 1975.
Operative procedures
Hepatic resection procedures included one trisegmentectomy, 27
lobectomies (11 left, 16 right) and one segmentectomy. There
were no significant differences between the two groups in surgical
procedures. Curative resection was defined as hepatic resection
with no residual HCC. Inoue et al.10 reported no differences in
outcome between the peeling-off technique (in which theMPVTT
is resected but the portal vein thrombus-bearing territory is pre-
served) and the en bloc technique (in which the portal veins are
reconstructed) when these were performed in association with
thrombectomy. All surgery in this study employed the peeling-off
technique.
Patient follow-up
Follow-up of patients after hepatectomy followed a strict protocol,
which did not change during the study period. Patients were
examined for recurrence by US and tumour markers such as AFP
and DCP every month and by CT every 3 months.
Recurrence after curative resection
Recurrence of HCC was examined in the 19 patients who had
undergone curative resection of primary HCC. Of these 19
patients, 18 had postoperative recurrence of HCC. The recurrence
pattern and therapy for recurrence were examined. The recur-
rence pattern was analysed according to the number of recurrent
nodules. This number included metastatic nodules in sites other
than the liver. Patients with HCC recurrence were divided into two
groups comprising, respectively, those with four or more recur-
rent nodules and those with fewer than four recurrent nodules.
The therapeutic modalities for recurrent HCC were resection,
radiofrequency ablation (RFA), transarterial chemoembolization
(TACE), regional chemotherapy and radiation. Repeat hepatec-
tomy for recurrent HCC in the liver was the treatment of choice
until recently, when local ablation therapy was recommended as
the initial treatment when the recurrent tumour measured <2 cm
in diameter and no more than three intrahepatic nodules were
found.11 Although all patients in this study had MPVTT, those
with intrahepatic recurrence of HCC were treated according to
the strategy described above, using local therapy, such as resection
and RFA, when possible. In patients with distant metastases, pul-
monary and bone metastases were resected if resection was pos-
sible, the metastases numbered less than four and intrahepatic
recurrence was under control.
Statistical analysis
All data are expressed as median value. Independent chi-squared
tests were used for categorical variables. Continuous variables
were compared by unpaired Student’s t-tests. Cumulative and
disease-free survival rates were obtained using the Kaplan–Meier
method. Differences in survival between groups were compared
for each variable using the log-rank test. The starting point for
the calculation of survival time was the date of operation. Death,
including deaths that were cancer- or liver-related, represented
the end-point. A P-value of <0.05 was considered to indicate
statistical significance.
Results
The median length of follow-up was 36 months (range: 18 days to
234 months). One patient died of operative morbidity. Overall
survival rates at 1, 3 and 5 years were 62.1%, 24.1% and 17.2%,
respectively (Fig. 1). The median survival time in all 29 patients
was 16.6 months.
Table 1 compares clinical and pathological variables in 5-year
survivors (n = 5) and non-survivors (n = 24). Preoperative serum
concentrations of DCP in 5-year survivors were significantly
lower than in non-survivors (P = 0.0052). In 19 patients, curative
resection (no residual HCC nodules) was performed. Non-
curative resection with residual HCC was performed in 10
patients. Overall survival rates at 1, 3 and 5 years were 73.4%,
36.8% and 26.3%, respectively, in patients who underwent cura-
tive resection and 38.5%, 0% and 0%, respectively, in those
who underwent non-curative resection (Fig. 2). All of the 5-year
survivors had undergone curative resection. All of the patients
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who underwent non-curative resection died within 2 years of
surgery. The difference in survival rates is not statistically
significant (P = 0.1336).
Overall survival in patients with high and low serum concen-
trations of DCP (2200 mAU/ml and <2200 mAU/ml, respec-
tively) was examined. The difference was statistically significant
(P = 0.0421). Disease-free survival in patients who underwent
curative resection is shown in Fig. 3. All except one of the 5-year
survivors had postoperative recurrence. There was no significant
difference in disease-free survival between 5-year survivors and
non-survivors. Recurrence patterns in the two groups are com-
pared in Table 2. Of 18 patients in whom HCC recurred after
curative resection, seven (38.8%) patients demonstrated less than
four nodules. Clear differences in recurrence patterns were
observed between the two groups. All of the 5-year survivors
showed fewer than four recurrent nodules, whereas only 21.4% of
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Figure 1 Overall survival rates after hepatic resection in patients with
hepatocellular carcinoma accompanied by main portal vein tumour
thrombus (n = 29)
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Figure 2 Comparison of overall survival in patients who underwent
curative (n = 19) vs. non-curative (n = 10) resection (P = 0.1336)
Table 1 Comparison of clinicopathological factors in non-survivors and 5-year survivors
Factor Non-survivors (n = 24) 5-year survivors (n = 5) P-value
Gender, male, n (%) 21 (87.5%) 4 (80.0%) 0.3896
Age, years, median (range) 56 (29–76) 51 (49–63) 0.3896
Total bilirubin, mg/dl, median (range) 0.9 (0.4–4.0) 1.1 (0.5–1.4) 0.3133
Albumin, g/dl, median (range) 3.7 (3.1–4.9) 3.8 (3.1–4.3) 0.5346
AST, U/l, median (range) 65 (19–1160) 36 (22–78) 0.0365a
ALT, U/l, median (range) 48 (10–338) 37 (25–300) 0.5913
Positive HBVs-Ag, n(%) 13 (54.2%) 3 (60.0%) 1.0000
Positive HCV-Ab, n (%) 9 (37.5%) 3 (60.0%) 0.6221
AFP, ng/ml, median (range) 4 001 (7–422 680) 2 325 (152.1–98 030) 0.1914
DCP, mAU/ml, median (range) 4 240 (24–75 000) 1 210 (18–2028) 0.0052a
DCP <2200 mAU/ml, n (%) 10 (41.7%) 5 (100%) 0.0421a
ICGR15, %, median (range) 12.0 (5.5–33.6) 8.7 (1.4–24.5) 0.1456
Main tumour size, cm, median (range) 8.5 (2.0–16.0) 3.9 (2.2–13.0) 0.1463
Tumour differentiation, moderate, n (%) 4 (16.7%) 2 (40.0%) 0.2709
Intrahepatic metastasis, n (%) 23 (95.8%) 3 (60.0%) 0.0684
Surgical curability, n (%) 14 (58.3%) 5 (100%) 0.1336
Blood loss, ml, median (range) 1 900 (493–23 000) 1 800 (1800–12 500) 0.5198
Transfusion rate, % 41.7% 40.0% 1.0000
aP < 0.05.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBVs-Ag, hepatitis B virus surface antigen; HCV-Ab, hepatitis C virus antibody;
AFP, alphafetoprotein; DCP, des-g-carboxy prothrombin; ICGR15, indocyanine green retention test at 15 min.
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non-survivors showed fewer than four recurrent nodules
(P = 0.0114). The most common organ in which recurrence
occurred was the liver; other sites of recurrence included lung,
bone, brain and peritoneum.
Statistically significant differences between the two groups in
the therapeutic modalities used for recurrent HCC emerged. Local
therapy, such as resection and RFA for recurrent nodules, was
performed more commonly in the 5-year survivors than in the
non-survivors (P = 0.0364).
Discussion
The prognosis of HCC patients with MPVTT is extremely poor,
even after the application of various therapeutic modalities, and
the optimal treatment of these patients remains controversial.
In previous reports, realistic therapeutic options have included
TACE, regional chemotherapy and radiation.12 Mean survival
times and response rates are <10 months and40%, respectively,
in patients who undergo TACE.13–16 With regional chemotherapy,
although much higher response rates, such as 63%, have been
reported, mean survival times are <1 year.17–23 Radiation therapy
gives much higher response rates, which can reach as much as
100%, but the maximum median survival time reported is 10.7
months.24–29 Thus, median survival time is <12 months in patients
who undergo therapeutic modalities other than surgery. In
hepatic resection, 5-year survival rates of 0–22.4% (Table 3) and
median survival times of 6.4–20.0 months have been reported.5–9
The current study found a 5-year survival rate of 17.4% and a
median survival of 16.6 months. These results suggest that hepatic
resection may represent the treatment of choice in patients with
HCC and MPVTT.
Reports of longterm survival are extremely rare in patients with
HCC accompanied by MPVTT. Numbers of 5-year survivors in
previous reports are shown in Table 3. These numbers are
extremely small and the factors that enable 5-year survival remain
unclear. In this study, preoperative serum concentrations of DCP
were significantly lower in 5-year survivors and all the 5-year
survivors underwent curative resection (no residual HCC). In
this study, the crucial cut-off point for serum concentrations
of DCP seems to be <2200 mAU/ml. A DCP has been reported to
represent a poor prognostic factor in patients with HCC under-
going hepatic resection30,31 or liver transplantation32,33 and is
reportedly associated with microvascular invasion by HCC cells.34
In this study, all patients had portal vein invasion; therefore other
mechanisms must be presumed to have had effect. Recently, Yue
et al.35 showed that DCP induces matrix metalloproteinase activ-
ity in HCC cells and Wang et al.36 showed that DCP induces
human vascular endothelial cell growth and migration. Fujikawa
et al.37 showed that HCC arterial vascularity strongly correlates
with expression of serum and tissue DCP, and suggested DCP
secreted from HCC cells may not act as a paracrine interaction
factor between HCC and vascular endothelial cells, but as an
autocrine driver. Recently, Murata et al.38 showed that cytoskeletal
changes during epithelial mesenchymal transition serve as a
crucial mechanism for DCP production in HCC. These findings
suggest that DCP may influence the malignant potential of HCC
cells by mechanisms other than vessel invasion.
Recurrence of HCC after hepatectomy and thrombectomy
occurs in most patients with MPVTT and is usually difficult to
control once it has occurred. The presence of HCC with MPVTT
has been considered to represent an end-stage condition with a
poor prognosis because tumour cells are likely to have spread
throughout the liver. However, the number of recurrent nodules
seems to be an important determinant of 5-year survival. In this
study, sites of recurrence in 5-year survivors included distant
metastatic sites, such as lung and bone. This suggests that the
recurrence of fewer than four nodules is not always associated
with further multiple recurrences. Therefore, in patients with
fewer than four recurrent nodules, local therapy may prolong
survival. In this study, two of the 5-year survivors underwent
resection of distant metastases, one underwent repeat hepatec-
tomy and one underwent RFA for intrahepatic recurrence. After
the local therapy, two patients remained free from HCC recur-
rence for >5 years. Therefore, in patients with fewer than four
recurrent nodules, local therapy such as resection and/or ablation
therapy may prolong survival. Thus, when the number of recur-
rent nodules is under four, local therapy should be selected with
the aim of achieving 5-year survival. The effectiveness of surgical
resection for pulmonary metastases from HCC after hepatectomy
has been shown previously.39 It is crucial to understand that local
therapy can be useful for recurrence after curative resection, even
in patients with MPVTT.
The prognosis remains extremely poor in patients who undergo
non-curative resection and demonstrate four or more recurrent
nodules. It is clear that other therapeutic strategies are necessary.
Regional chemotherapy, including interferon-a (IFN-a) may
be another option for adjuvant therapy after surgery. Nagano40
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Figure 3 Comparison of disease-free survival in 5-year survivors
(n = 5) and non-survivors (n = 24) after curative resection
(P = 0.1134)
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demonstrated that adjuvant chemotherapy with IFN-a and
5-fluorouracil (5-FU) is useful and prolongs survival. In HCC
patients with MPVTT in whom curative resection cannot be
performed, IFN-a and 5-FU therapy is effective and curative
resection sometimes becomes possible after this therapy.41 The
combination of IFN-a and 5-FU therapy and hepatic resection
may represent a promising strategy. The effects of sorafenib, a
newly developed biologic therapy for non-resectable HCC, should
be clarified in these patients.42
In conclusion, factors that relate positively to 5-year survival
after hepatic resection seem to be low serum concentrations of
DCP and curative resection. In patients who show recurrence of
HCC,thepresenceof fewer than four recurrentnodules seems tobe
a good predictor of longterm survival. Local therapy, such as
surgical resection and/or ablation therapy, may be useful for this
type of recurrence. Further therapeutic strategies are necessary in
patients with high serum concentrations of DCP, who cannot
undergo curative resection and have four or more recurrent
nodules.
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